NCT03954574 Pulmonary Hemodynamics During Exercise - Research Network
| NCT ID | NCT03954574 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Graz |
| Condition | Pulmonary Circulation Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2018-12-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2018-12-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this Clinical Research Collaboration is to investigate the prognostic implications of pulmonary hemodynamics during exercise based on a large scale multi-centre approach by using retrospective and prospective analysis of hemodynamic data.
Eligibility Criteria
Inclusion Criteria: * Patients (females and males; age: above 18yrs) with intermediate or high echocardiographic probability of PH and/or unexplained dyspnea, and/or associated conditions for PAH as clinical indication for RHC at rest and exercise * Written informed consent of participating subjects after being fully briefed (for prospective analysis) Exclusion Criteria: * Patients with incomplete hemodynamic data at rest or exercise * Patients without sufficient follow-up data (information on survival / lung transplantation) * advanced tumour disease or other diseases with a short life expectancy, except pulmonary vascular diseases * advanced heart failure with pulmonary arterial wedge pressure (PAWP) \> 18 mmHg at rest * uncontrolled systemic arterial hypertension (RR values \> 160/100 mmHg at rest) * FEV1\<50% predicted * TLC\<60% predicted
Contact & Investigator
Horst Olschewski, MD
STUDY CHAIR
Medical University of Graz
Frequently Asked Questions
Who can join the NCT03954574 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Circulation Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03954574 currently recruiting?
Yes, NCT03954574 is actively recruiting participants. Contact the research team at gabor.kovacs@klinikum-graz.at for enrollment information.
Where is the NCT03954574 trial being conducted?
This trial is being conducted at Phoenix, United States, Los Angeles, United States, Baltimore, United States, Boston, United States and 11 additional locations.
Who is sponsoring the NCT03954574 clinical trial?
NCT03954574 is sponsored by Medical University of Graz. The principal investigator is Horst Olschewski, MD at Medical University of Graz. The trial plans to enroll 1,500 participants.